Skip to main content
BKYI
NASDAQ Technology

BIO-key Q3: $4.01/Share Loss, Going-Concern Warning, Ineffective Controls

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Security & Protection Stocks · Industrial
Sentiment info
Negative
Importance info
8
Price
$2.13
Mkt Cap
$4.335M
52W Low
$1.55
52W High
$11.1
52W Position info
37% above low
Off High info
81% below high
Rel. Volume
Market data snapshot near publication time

BKYI sits 37% above its 52-week low of $1.55.

Summary

BIO-key reported a Q3 net loss of $886,083 ($4.01 per share after a $4.5M non-cash warrant-inducement dividend) on $1.48M revenue, and disclosed substantial doubt about its ability to continue as a going concern with only $2.22M of cash.


Key Events · Earnings and Guidance · BKYI

  • Going-Concern Warning Disclosed

    Management states the Company does not have enough cash for twelve months of operations and will need additional third-party financing; the financials carry no adjustments for recoverability if it cannot continue.

  • Q3 Loss Narrowed on Flat Revenue

    Net loss was $886,083 versus $964,849 a year earlier; revenue was $1,482,781 versus $1,549,706, with license fees up 39% to $1,275,249 offsetting a 97% drop in hardware to $12,404.

  • $4.5M Non-Cash Warrant Dividend

    The August 10, 2026 warrant inducement produced a deemed dividend of $4,502,004, pushing net loss available to common stockholders to $5,388,087, or $4.01 per share.

  • Cash Down to $2.2M

    Cash and equivalents were $2,219,428 at September 30, 2026 versus $2,694,663 at December 31, 2025, against roughly $750,000 per month of required operating spend.


Analysis · BKYI · Technology

The Q3 10-Q carries an explicit going-concern warning: management states it does not have enough cash for twelve months of operations and will need third-party financing. With cash down to $2.22M from $2.69M at year-end and roughly $750,000 of monthly operating spend, runway is measured in months, not years. Most of the headline $4.01 per-share loss is accounting — a $4.5M non-cash deemed dividend from the August warrant inducement — while the underlying net loss actually narrowed to $886,083 from $964,849. Revenue was roughly flat at $1.48M as license growth (+39%) offset a 97% collapse in hardware sales. On top of the liquidity problem, management concluded disclosure controls were ineffective — a governance flag.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BKYI was trading at $2.13 on NASDAQ in the Technology sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $1.55 to $11.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BKYI - Latest Insights

BKYI
Nov 13, 2026, 7:59 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.68
Real-time Price: $2.12 info
Change: -$0.560 (-21%) info
Market Cap: $4.315M info
BKYI
Oct 30, 2026, 5:02 PM EDT
Filing Type: S-1/A
Importance Score:
7
Price at Filing: $2.69
Real-time Price: $2.12 info
Change: -$0.570 (-21%) info
Market Cap: $4.315M info
BKYI
Oct 09, 2026, 5:00 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $2.12 info
Change: +$0.520 (+33%) info
Market Cap: $4.315M info
BKYI
Oct 02, 2026, 5:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $2.12 info
Change: +$0.060 (+3%) info
Market Cap: $4.315M info
BKYI
Sep 23, 2026, 7:59 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.40
Real-time Price: $2.12 info
Change: -$0.2802 (-12%) info
Market Cap: $4.315M info